Insight Molecular Diagnostics, Inc. (IMDX)
2.49
+0.03
(+1.22%)
USD |
NASDAQ |
Nov 06, 16:00
2.50
+0.01
(+0.40%)
After-Hours: 20:00
Insight Molecular Diagnostics Enterprise Value : 65.37M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 65.37M |
| November 05, 2026 | 64.39M |
| November 04, 2026 | 70.59M |
| November 03, 2026 | 73.53M |
| November 02, 2026 | 77.44M |
| October 30, 2026 | 80.70M |
| October 29, 2026 | 87.88M |
| October 28, 2026 | 87.88M |
| October 27, 2026 | 87.23M |
| October 26, 2026 | 82.01M |
| October 23, 2026 | 76.46M |
| October 22, 2026 | 76.79M |
| October 21, 2026 | 82.66M |
| October 20, 2026 | 82.99M |
| October 19, 2026 | 78.42M |
| October 16, 2026 | 82.33M |
| October 15, 2026 | 83.97M |
| October 14, 2026 | 75.16M |
| October 13, 2026 | 81.68M |
| October 12, 2026 | 87.55M |
| October 09, 2026 | 94.08M |
| October 08, 2026 | 91.14M |
| October 07, 2026 | 97.02M |
| October 06, 2026 | 94.41M |
| October 05, 2026 | 103.87M |
| Date | Value |
|---|---|
| October 02, 2026 | 96.36M |
| October 01, 2026 | 97.34M |
| September 30, 2026 | 101.26M |
| September 29, 2026 | 94.41M |
| September 28, 2026 | 87.88M |
| September 25, 2026 | 112.02M |
| September 24, 2026 | 113.00M |
| September 23, 2026 | 111.70M |
| September 22, 2026 | 119.20M |
| September 21, 2026 | 114.96M |
| September 18, 2026 | 114.63M |
| September 17, 2026 | 113.00M |
| September 16, 2026 | 100.93M |
| September 15, 2026 | 115.28M |
| September 14, 2026 | 115.28M |
| September 11, 2026 | 121.16M |
| September 10, 2026 | 113.98M |
| September 09, 2026 | 117.89M |
| September 08, 2026 | 123.44M |
| September 04, 2026 | 118.87M |
| September 03, 2026 | 118.55M |
| September 02, 2026 | 114.96M |
| September 01, 2026 | 109.41M |
| August 31, 2026 | 112.02M |
| August 28, 2026 | 118.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | -137.08M |
| Agenus, Inc. | 506.92M |
| Amgen, Inc. | 289.86B |
| Anika Therapeutics, Inc. | 176.07M |
| BioCryst Pharmaceuticals, Inc. | 2.422B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.26M |
| Revenue (Quarterly) | 0.239M |
| Total Expenses (Quarterly) | 11.50M |
| EPS Diluted (Quarterly) | -0.3064 |
| Gross Profit Margin (Quarterly) | -202.5% |
| Profit Margin (Quarterly) | -4.71K% |
| Earnings Yield | -59.65% |
| Normalized Earnings Yield | -47.92 |